title: Genetic polymorphisms in the 5-hydroxytryptamine type 3B receptor gene and paroxetine-induced nausea.
abstract: Selective serotonin reuptake inhibitor (SSRI)-induced nausea can be severe enough to lead to early treatment discontinuation. However, it is currently not possible to predict the occurrence of nausea before the initiation of SSRI treatment. In this study, we investigated the effect of genetic polymorphisms in the 5-hydroxytryptamine type 2A, 3A, and 3B (5-HT3B) receptors, 5-HT transporter, and CYP2D6 genes on the incidence of paroxetine-induced nausea. A consecutive series of 72 Japanese patients with depressive or anxiety disorders were treated with paroxetine. Paroxetine-induced nausea was assessed by a pharmacist and was observed in 29.2% of the patients. A significant (nominal p=0.00286) association was found between the incidence of nausea and the -100_-102AAG insertion/deletion polymorphism of the 5-HT3B receptor gene. No significant associations were observed between the other genetic polymorphisms and the incidence of nausea. The -100_-102AAG deletion variant of the 5-HT3B receptor gene may affect paroxetine-induced nausea.
authors: Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
authors: Misuzu
authors: M
authors: Tanaka
authors: Daisuke
authors: D
authors: Kobayashi
authors: Yuko
authors: Y
authors: Murakami
authors: Norio
authors: N
authors: Ozaki
authors: Tatsuyo
authors: T
authors: Suzuki
authors: Nakao
authors: N
authors: Iwata
authors: Koichi
authors: K
authors: Haraguchi
authors: Ichiro
authors: I
authors: Ieiri
authors: Naoko
authors: N
authors: Kinukawa
authors: Masako
authors: M
authors: Hosoi
authors: Hisakazu
authors: H
authors: Ohtani
authors: Yasufumi
authors: Y
authors: Sawada
authors: Kazunori
authors: K
authors: Mine
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000097:blood; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000235:genetics; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D015994:Incidence; D007564:Japan; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000209:etiology* / Q000235:genetics; D017374:Paroxetine / Q000009:adverse effects* / Q000097:blood; D011110:Polymorphism, Genetic; D044406:Receptors, Serotonin, 5-HT3 / Q000235:genetics*; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000097:blood; D012720:Severity of Illness Index
chemical_list: D018687:Antidepressive Agents, Second-Generation; D017374:Paroxetine; D044406:Receptors, Serotonin, 5-HT3; D017367:Selective Serotonin Reuptake Inhibitors